Takeda Pharmaceutical (TAK) Retained Earnings (2017 - 2026)
Takeda Pharmaceutical's (TAK) quarterly Retained Earnings came in at $4.5 billion in Q1 2026, down 41.64% year-on-year from $7.8 billion in Q1 2025, and down 36.2% quarter-over-quarter from $7.1 billion in Q4 2025.
Takeda Pharmaceutical (TAK) Retained Earnings (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Retained Earnings history runs 10 years deep, the most recent figure standing at $4.5 billion for Q1 2026.
- On a quarterly basis, Retained Earnings fell 41.64% year-over-year to $4.5 billion in Q1 2026; TTM through Mar 2026 was $4.5 billion, a 41.64% decrease from a year earlier, with the FY2026 full-year figure at $4.7 billion, down 39.3% from the prior year.
- Retained Earnings fell to $4.5 billion in Q1 2026 per TAK's latest filing, from $7.1 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $12.7 billion in Q1 2022 and bottomed at $4.5 billion in Q1 2026.
- The 5-year median for Retained Earnings is $9.4 billion (2024), against an average of $9.3 billion.
- Across the five-year window, Retained Earnings retreated 3.67% in 2023 and slumped 41.64% in 2026, its largest moves.
- Year by year, Retained Earnings stood at $10.7 billion in 2022, then declined by 11.45% to $9.4 billion in 2023, then declined by 10.14% to $8.5 billion in 2024, then slipped by 16.16% to $7.1 billion in 2025, then slumped by 36.2% to $4.5 billion in 2026.
- Per Business Quant, the three latest TAK Retained Earnings figures stand at $4.5 billion (Q1 2026), $7.1 billion (Q4 2025), and $7.8 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -319.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.54 Bn |
| Dec 31, 2025 | 7.12 Bn |
| Sep 30, 2025 | 7.80 Bn |
| Jun 30, 2025 | 7.99 Bn |
| Mar 31, 2025 | 7.78 Bn |
| Dec 31, 2024 | 8.49 Bn |
| Jun 30, 2024 | 8.60 Bn |
| Mar 31, 2024 | 9.39 Bn |
| Dec 31, 2023 | 9.45 Bn |
| Sep 30, 2023 | 10.01 Bn |
| Jun 30, 2023 | 10.87 Bn |
| Mar 31, 2023 | 11.65 Bn |
| Dec 31, 2022 | 10.67 Bn |
| Sep 30, 2022 | 11.08 Bn |
| Jun 30, 2022 | 11.29 Bn |
| Mar 31, 2022 | 12.73 Bn |
| Dec 31, 2021 | 12.90 Bn |
| Sep 30, 2021 | 14.09 Bn |
| Jun 30, 2021 | 14.31 Bn |
| Mar 31, 2021 | 14.26 Bn |